Patents Examined by Jeffrey Stucker
  • Patent number: 10227398
    Abstract: The present invention provides anti-C1q antibodies and methods of using the same.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: March 12, 2019
    Assignee: Annexon, Inc.
    Inventors: Arnon Rosenthal, Michael Leviten
  • Patent number: 10151762
    Abstract: The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: December 11, 2018
    Assignee: Proclara Biosciences, Inc.
    Inventors: Rajaraman Krishnan, Richard Fisher
  • Patent number: 10053507
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: August 21, 2018
    Assignee: AMGEN INC.
    Inventors: Cen Xu, Agnes Eva Hamburger
  • Patent number: 10039756
    Abstract: The disclosure relates to methods and compositions for reducing memory loss. Specifically, methods of using inhibitors of GAT-3 polypeptide activity to reduce memory loss in mammals suffering from Alzheimer's disease (AD) are provided. Further provided are methods for identifying a mammal as having AD by detecting the presence of an elevated level of gamma-aminobutyric acid (GABA) within a mammal's brain.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: August 7, 2018
    Assignee: The Penn State Research Foundation
    Inventors: Gong Chen, Zheng Wu, Ziyuan Guo
  • Patent number: 10010574
    Abstract: A silk peptide having neuroprotective and neurofunctional activities and its preparation method are discussed. One method relates to preparing silk protein preferably having neuroprotective activity with weight average molecular weight of 200-100,000 by hydrolysis of silk fibroin; also discussed are a composition for preventing or treating brain disease comprising silk peptide and pharmaceutically acceptable carrier, and a composition for improving brain function.
    Type: Grant
    Filed: July 31, 2004
    Date of Patent: July 3, 2018
    Assignee: BRAINGUARD CO., LTD.
    Inventors: Sung Su Kim, Cheol Hyoung Park, Sang-Hyung Lee, Wan-Seok Joo, Won Bok Lee
  • Patent number: 9822169
    Abstract: The invention includes the use of the HE/HE4a markers to assess ovarian cancer in a subject. Included also are compositions and methods of using HE/HE4a marker for diagnosis, grading and staging of ovarian cancers, determining prognosis and treatment effectiveness of a subject who has been diagnosed with ovarian cancer.
    Type: Grant
    Filed: February 17, 2011
    Date of Patent: November 21, 2017
    Assignees: PACIFIC NORTHWEST DIABETES RESEARCH INSTITUTE, FUJIREBIO DIAGNOSTICS, INC.
    Inventors: Ingegerd Hellstrom, Karl-Erik Hellstrom, John Raycraft, Christian Fermér, Eva Roijer
  • Patent number: 9822178
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: November 21, 2017
    Assignee: AMGEN INC.
    Inventors: Cen Xu, Agnes Eva Hamburger
  • Patent number: 9822338
    Abstract: Methods, compositions and kits for producing functional neurons, astroctyes, oligodendrocytes and progenitor cells thereof are provided. These methods, compositions and kits find use in producing neurons, astrocytes, oligodendrocytes, and progenitor cells thereof for transplantation, for experimental evaluation, as a source of lineage- and cell-specific products, and the like, for example for use in treating human disorders of the CNS. Also provided are methods, compositions and kits for screening candidate agents for activity in converting cells into neuronal cells, astrocytes, oligodendrocytes, and progenitor cells thereof.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: November 21, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Marius Wernig, Thomas C. Sudhof, Thomas Vierbuchen, Austin Ostermeier, Zhiping Pang
  • Patent number: 9757398
    Abstract: The invention provides compositions and methods for treatment of Alzheimer's disease. Such methods entail administering agents that induce a beneficial immune and therapeutic response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In certain preferred embodiments of such methods, a preferred agent is amyloid beta peptide in combination with Sphingosine-1-phosphate, preferably delivered in certain embodiments in a liposomal formulation.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: September 12, 2017
    Assignee: EUROESPES BIOTECNNOLOGIA, S.L.
    Inventors: Carmen Vigo, Ramon Cacabelos
  • Patent number: 9708394
    Abstract: The present invention provides anti-C1q antibodies and methods of using the same.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: July 18, 2017
    Assignee: Annexon, Inc.
    Inventors: Arnon Rosenthal, Michael Leviten
  • Patent number: 9676851
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 13, 2017
    Assignee: AMGEN INC.
    Inventors: Cen Xu, Agnes Eva Hamburger
  • Patent number: 9670273
    Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: June 6, 2017
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose Saldanha, Tarlochan S. Nijjar
  • Patent number: 9625459
    Abstract: Disclosed is a method for diagnosing Alzheimer's disease (AD) wherein A?-specific antibodies in a biological sample of a person that is suspected of having AD are detected comprising the following steps: —contacting the sample with A?-aggregates or with particles having A?-aggregate like surfaces and allowing the A?-specific antibodies to bind to the A?-aggregates, and —detecting the A?-specific antibodies bound to the A?-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS); and wherein the amount of A?-specific antibodies detected is compared with the amount in a sample of known AD status.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: April 18, 2017
    Assignee: AFFIRIS AG
    Inventors: Guenther Staffler, Andreas Mairhofer, Achim Schneeberger, Martina Lutterova, Walter Schmidt, Frank Mattner
  • Patent number: 9618524
    Abstract: The disclosure relates to an in vitro technology of detecting presence of a plaque particle, isolating the plaque particle followed by its composition analysis in several diseases states or before the disease sets in. A mechanism and a process leading to plaque formation, identifying a component in the mechanism of plaque formation, an identification of a biomarker for diagnosis/early diagnosis of plaque associated disease is described. A method of screening a candidate agent as an anti-plaque agent using flow cytometer, mass spectrometer and specific biomarkers is performed. Provided also are kits for use in practicing embodiment of the methods. A plaqueproteome database is also generated with novel protein sequences for diagnosis and specific antibodies for specific proteins are also disclosed.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: April 11, 2017
    Assignee: Plaxgen Inc.
    Inventor: Shanmugavel Madasamy
  • Patent number: 9617332
    Abstract: The present disclosure relates to a conformational specific antibody molecule recognizing a conformational epitope of human trimeric or tetrameric A? oligomers, wherein said antibody molecule does not bind human monomeric A? 1-42 or human Ap 1-42 dimers; and pharmaceutical and diagnostic compositions comprising said antibody molecule as well as methods using same.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: April 11, 2017
    Assignee: GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN
    Inventor: Thomas Bayer
  • Patent number: 9586999
    Abstract: Disclosed are compositions and methods related to improving pharmacological properties of bioactive compounds targeting nervous system.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: March 7, 2017
    Assignee: University of Utah Research Foundation
    Inventors: Grzegorz Bulaj, H. Steve White
  • Patent number: 9580493
    Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: February 28, 2017
    Assignees: Biogen International Neuroscience GmbH, University of Zürich
    Inventors: Andreas Weihofen, Jan Grimm, Christoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
  • Patent number: 9581604
    Abstract: Desmosterol alone, the combination of desmosterol and amyloid beta, the combination of desmosterol and gelsolin and the combination of desmosterol, amyloid beta and gelsolin can be used as in-blood biomarkers for Alzheimer's disease or mild cognitive impairment. A method for evaluating the effect of a candidate for a therapeutic agent to treat Alzheimer's disease or mild cognitive impairment, a method for aiding the diagnosis of Alzheimer's disease or mild cognitive impairment, and a method for diagnosing Alzheimer's disease or mild cognitive impairment are provided in which the biomarkers are used.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: February 28, 2017
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoshiaki Sato, Ken Aoshima, Francois Bernier
  • Patent number: 9567393
    Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognizes oligomeric A? that is resistant to denaturation by SDS but does not bind monomeric, fibrillar or other oligomeric forms of A? that are generated in vitro.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: February 14, 2017
    Inventors: Michael Sierks, Srinath Kasturirangan
  • Patent number: 9535072
    Abstract: Methods aiding in the diagnosis of certain neuropathies are disclosed, in which the titer of antibodies to a disulfated heparin disaccharide is assessed in a test sample from an subject. Also disclosed are apparatus and kits that can be used in the methods of the invention.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: January 3, 2017
    Assignee: WASHINGTON UNIVERSITY
    Inventor: Alan Pestronk